Bridge Bio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics aimed at treating cancers associated with RAS and PI3K oncogenes. With a commitment to improving patient outcomes, BBOT has successfully secured $200 million in private financing to advance its next-generation pipeline. The company emphasizes precision medicine and operates within the oncology space, fostering a collaborative environment for its regulatory affairs team and other cross-functional teams.